Pharmaceutical stocks started to rise again is only a matter of time With all sorts of biotech companies have launched the vaccine, main pharmaceutical shares is expected to benefit from Moderna and companies such as Pfizer has been rising over the past year, but in the past two months, because of the financial impact caused by vaccine sales far above analysts' expectations, their share prices have appeared almost exponential increases.
Investors now focus on future sustainability of vaccine revenue.
Pfizer noted that it expects to recommend a third booster shot later this year, and that the rising number of cases of the mutant strain could keep demand for additional vaccines high This month,Moderna increased its weighting to the 3% ceiling from 0.85%, while Pfizer increased its weighting to 1.96% from 0.47%. The overall weighting of the healthcare sector in the BUZZ index rose to 9.8% from 5.7%, indicating growing investor confidence in the sector.